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Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) is one of
the most commonly used measures in cancer care but in its current
form cannot be used in economic evaluation because it does not incor-
porate preferences. We address this gap by estimating a preference-
based measure for cancer from the EORTC QLQ-C30. Methods: Factor
analysis, Rasch analysis, and other psychometric analyseswere under-
taken on a clinical trial dataset of 655 patients with multiple myeloma
to derive a health state classification system amenable to valuation.
Second a valuation study was conducted of 350 members of the UK
general population using time trade-off. Mean and individual-level
multivariate regression models were fitted to derive preference
weights for the classification system. Results: The health state classi-
t
E
d
r
b
C
c
t
h
t
Q
t
d
C
t
a
M
s
l
P
d De
1 4D
al So
oi:10.1016/j.jval.2011.01.004fication system has eight dimensions (physical functioning, role func-
tioning, social functioning, emotional functioning, pain, fatigue and
sleep disturbance, nausea, constipation, and diarrhea) with four or five
levels each. Regression models have few inconsistencies (0 to 2) in
estimated preference weights and small mean absolute error ranges
(0.046 to 0.054). Conclusions: It is feasible to derive a preference-based
measure from the EORTC QLQ-C30 for use in economic evaluation.
Future research will extend this to other countries and replicate across
other patient groups.
Keywords: cancer, EORTC QLQ-C30, preference-basedmeasures, QALY,
utility.
Copyright © 2011, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Generic preference-based measures, such as EQ-5D [1], HUI3 [2] or
SF-6D [3,4] are widely used to calculate quality-adjusted life years
(QALYs) for use in economic evaluation. The EQ-5D is themost com-
monly used generic preference-based measure (PBM) and is cur-
rently recommended by the National Institute of Health and Clinical
Excellence in England and Wales [5]. Generic measures of health,
however, have been found to be inappropriate or insensitive for
somemedical conditions [6] and for cancer in particular [7]. Further-
ore, clinicians and researchers often choose to include condition-
pecific profile measures in trials rather than generic PBMs because
hey needmeasures that are sensitive to the effects of interventions
cross a range of relevant symptoms, side effects, and aspects of
unctioning andquality of life, and are recommendedby theUS Food
nd Drug Administration [8]. Condition-specific measures, such as
he European Organisation for Research and Treatment of Cancer
ore quality of life questionnaire (EORTC QLQ-C30), have great
linical utility because they summarize a number of symptom and
omain-specific scales. Because they are not preference-based,
hey provide a description rather than a valuation, and therefore
annot be used to estimate QALYs.
* Address correspondence to: Donna Rowen, Health Economics an
niversity of Sheffield, Regent Court, 30 Regent Street, Sheffield, S
E-mail: d.rowen@sheffield.ac.uk.
098-3015/$36.00 – see front matter Copyright © 2011, Internation
ublished by Elsevier Inc.There are three ways in which researchers can estimate utili-
ies to produce QALYs for a trial where a generic PBM such as
Q-5D is unavailable: undertake ‘mapping,’ value ‘vignettes,’ or
erive a PBM from the existing condition-specific measure.
Mapping (also known as cross-walking or estimating exchange
ates between instruments) involves predicting the relationship
etween the non-preference-based measure, for example QLQ-
30, and a generic PBM, for example EQ-5D, using statistical asso-
iation. Typically mapping by statistical association uses two da-
asets; an estimation dataset contains respondents’ self-reported
ealth using, for example, QLQ-C30 and EQ-5D and the study da-
aset containing only QLQ-C30. A statistical relationship between
LQ-C30 and EQ-5D is estimated using regression techniques on
he estimation dataset and the results are applied to the study
ataset to obtain estimated EQ-5D utilities. Alternatively the QLQ-
30 can be mapped to patient valuations of own health (rather
han EQ-5D) [9], but general population values are deemed more
ppropriate than patient values for use in resource allocation [5].
apping is a second best alternative to using a PBM directly in a
tudy because mapped estimates can have large errors, particu-
arly when mapping from condition-specific measures to generic
BMs [10]. Mapping is only valid if both measures are appropriate
cision Science, School of Health and Related Research (ScHARR),
A, UK.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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722 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 2 1 – 7 3 1for the patient population, which is unlikely to be the case for
generic PBMs administered to cancer patients [7].
An alternative solution to estimate utilities when generic PBMs
are unavailable or inappropriate is to value bespoke descriptions;
that is, ‘vignettes,’ that describe health states experienced by pa-
tients in the trial. Only a selection of all health states experienced
will be valued, however, so this will not fully take into account
variation across individuals and treatments. Furthermore, be-
cause observed health states differ across trials for different treat-
ments, vignettes need to be created and valued for each trial. This
reduces comparability across trials and treatments.
It has been argued that a better approach inmany caseswould be
to develop a PBM from the condition-specific questionnaire specifi-
cally designed for that condition [11]. Typically this requires reducing
the length of the questionnaire to obtain a health state classification
system (HSC) that remains responsive andvalid for the condition but
that is amenable to valuation. AHSC typically consists of four to nine
dimensions eachwith three to six severity levels,where eachdimen-
sion is produced using one or two items from the original question-
naire. Preference weights for the HSC are then obtained from a rep-
resentative sample of the general population.
This study appliesmethods originally developed in the estima-
tion of a generic PBM of health from the SF-36 [3,12] and subse-
quently used with condition-specific measures in urinary inconti-
nence [13], asthma [14,15], and overactive bladder [16,17]). First, an
HSC amenable to valuation was derived from the QLQ-C30 using
psychometric analysis, factor analysis, and Rasch analysis on a
dataset of patients with multiple myeloma. Subsequently a valu-
ation survey was conducted asking members of the general pop-
ulation to value a sample of states defined by the HSC. Finally,
regression models were estimated on the results of the valuation
survey to estimate preferenceweights to produce utility estimates
for all health states defined by the HSC.
EORTC QLQ-C30
The QLQ-C30 is one of the most commonly used measures in can-
cer [18] and dominates cancer clinical trials in Europe and Canada.
he QLQ-C30 contains 30 questions covering the most common
ancer symptoms (such as pain, fatigue, nausea, and vomiting)
nd various aspects of function (including physical, role, social,
motional, and cognitive functioning). The QLQ-C30 is summa-
ized using 14 scales, each representing a particular symptom or
spect of function, plus one global quality of life scale (based on
wo global questions). Its validity has been well established for
any conditions in cancer.
Although the QLQ-C30 has proved to be useful for demonstrat-
ng treatment benefits, it cannot be used in economic evaluation in
ts current form because it does not incorporate preference infor-
ation. It generates a profile of scores representing a range of
ymptoms and aspects of functioning and a global quality of life
core, but it does not currently generate a single preference-based
ndex of quality of life required for economic evaluation using
ALYs. Further, the number of items and scales is too large to be
menable to valuation using preference elicitation techniques
uch as time trade-off (TTO) [19] and standard gamble ([20].
EORTC QLQ-C30 multiple myeloma patient dataset
The dataset used to derive the HSC contains data on patients
newly diagnosed with multiple myeloma. Data were collected in
VISTA, a Phase III randomized open-label trial (ClinicalTrials.gov
No. NCT00111319) completed in June 2007. Patients were asked to
complete the QLQ-C30 Version 3 at screening visit, Day 1 of each
cycle of treatment (Cycles 1–9), end of treatment visit and in post-
treatment phase (every 6 or 8 weeks) until disease progression.
The screening phase of the dataset (n  655; 49.9% women, 87%
white, mean age of 71.9  5.4 years) was used to select items forthe HSC. This phase was selected as the responses do not suffer
from biases caused by attrition. The selections were then vali-
dated using data at Cycle 5 of treatment (n  471) in the trial.
Methods
The overall process of creating the condition-specific preference-
based EORTC-8D measure from the EORTC QLQ-C30 is outlined in
Figure 1. Steps I and III derive a health state classification from the
QLQ-C30 and Steps IV and V enable utility values to be estimated
for all health states.
The aim of Steps I and III was to produce a multidimensional
HSC from the QLQ-C30 that is amenable to valuation with a min-
imum loss of information and subject to the constraint that re-
sponses from QLQ-C30 can be unambiguously mapped onto it.
This implies that the text of the items should be altered as little as
possible. The methodology outlined here uses a combination of
classical psychometric and Rasch analysis to select dimensions,
items and severity levels of the QLQ-C30 for inclusion in the HSC
[17]. SPSS version 15 (2005, SPSS Inc, Chicago, IL) was used for the
factor analysis and Rasch Unidimensional Measurement Models
(RUMM2020) (RUMM Laboratory Pty Ltd, 1997–2004) was used for
Fig. 1 – Flow diagram of the process used to derive the
EORTC-8D from the EORTC QLQ-C30.the Rasch analysis.
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723V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 2 1 – 7 3 1Step I: Establishing factors
Multidimensional HSC for valuation should have structural inde-
pendence between dimensions to avoid nonsensical states [2],
meaning there must be little correlation between dimensions in
our HSC. The large literature on the QLQ-C30 focuses upon its use
as a profile measure, but here we wish to determine dimensions
across all items that can be applied in a preference basedmeasure,
ignoring whether these are functions or symptoms. The QLQ-C30
has 14 scales, and this is too large to be amenable to valuation. The
size of the classification system is constrained by the number of
dimensions that respondents can value, and as people can only
process between five and nine pieces of information [21] we are
constrained to this number of dimensions. We therefore priori-
tized across dimensions to limit the size of the HSC.
Factor analysis can be used for a set of observed items to iden-
tify structurally independent factors or dimensions by highlight-
ing underlying factors that explain patterns of correlation [22] and
has been successfully used elsewhere to establish the dimension-
ality of a PBM derived from an existing profile measure [15,17,23].
We use this approach to establish factors (rather than use the 14
scales of the QLQ-C30) as factor analysis enables correlations to be
determined across items and scales and this can inform the choice
of dimensions to be used in the health state classification. We
applied factor analysis to 27 of the 30 items of the QLQ-C30, (ex-
cluding global quality of life and financial impact items as these
are inappropriate for a PBM of health-related quality of life) and
factors were determined using a varimax component matrix (to
simplify the interpretation of the factors) and eigenvalues. A range
of factor structures were investigated, and the final solution was
chosen using the proportion of variance explained, number of
eigenvalues greater than one and the number and difference be-
tween cross-loading items. Itemswere divided into factors accord-
ing to their ‘loadings,’ the correlation between the item and the
factor. Items loading greater than 0.35 were selected and cross-
loading items (difference between cross loadings  0.2) were in-
cluded in the factor that made most sense clinically. Rasch anal-
ysis was also used to examine the extent to which items belong to
a single factor (see below). Results were discussed with our team’s
clinical expert (GV) to ensure the dimensionality of the HSC made
sense clinically. The findings were analyzed to establish if they
were in accordance with the QLQ-C30 scaling.
Step II: Dimension and item selection
Each dimension in a HSC of a PBM is usually represented by just
one or two items to ensure the HSC is amenable to valuation. We
used the following conventional psychometric criteria to inform
the selection of items: distribution of responses across categories
of response (including floor effects and ceiling effects), percentage
of missing data, correlation of item to dimension, and responsive-
ness to change over two points in time using standardized re-
sponse mean (SRM).
A further technique often used [15,17,23] to select items is Ra-
sch analysis [24]. This is a mathematical technique that converts
qualitative (categorical) responses to points on a continuous (un-
measured) latent scale using a logit model [25]. It can be used to
assess items regarding: whether or not an item fits the model,
severity of health problem covered, if response choices are appro-
priately ordered (responders can distinguish between response
levels), and differential performance between populations (known
as differential item functioning [DIF] where item responses, for
example, differ across men and women with the same underlying
traits) [17]. Items that fit the Rasch model, cover the full severity
range, have ordered response choices, and do not suffer from DIF
by sex or age, based on analysis of variance at the 1% level of
statistical significance), were considered as candidates for inclu-
sion in the HSC. Items that did not fit the Rasch model (item levelchi-square P 0.01) were removed; all other items were retained
nd the Rasch analysis re-estimated. We used the following
riteria to assess the Rasch model for each dimension: item-
rait interaction (whether data fitted the Raschmodel for groups
f respondents with similar underlying health), person separa-
ion index (whether the Rasch model could discriminate be-
ween responders), item fit and person fit residuals (divergence
etween expected and observed responses per respondent), and
tem range and spread at logit zero (whether items covered a
ide severity range).
The final selection of dimensions, items, and levels was
ased on performance using the psychometric tests and Rasch
nalysis while ensuring that health states made clinical sense
nd were amenable to valuation. The process involved judg-
ent by our clinical expert (GV) and consideration of wording of
he HSC.
Step III: Validation
To select a validation dataset the SRM was calculated for all
cycles and it was found that the SRM increases with each cycle
until Cycle 9. However the trial population reduces in size each
period. We therefore decided to use a mid-cycle treatment to
validate responses because these are periods with a large num-
ber of responses where responses have changed. We avoided
using cycles near the end of treatment because sample size was
less than half the original trial population and there was danger
Table 1 – Characteristics of respondents.
Included
respondents
(n  344)*
South
Yorkshire†
England†
Mean age (s.d.) 47.8 (18.5) NA NA
Age distribution
18–40 38.6% 41.2% 41.6%
41–65 42.7% 39.1% 39.1%
Over 65 17.2% 19.7% 19.3%
Female 61.9% 51.2% 51.3%
Married/partner 57.0% NA NA
Employed or self-employed 43.6% 56.1% 60.9%
Unemployed 0.6% 4.1% 3.4%
Long-term sick 6.4% 7.7% 5.3%
Full-time student 7.3% 7.5% 7.3%
Retired 24.7% 14.4% 13.5%
Own home outright or with
a mortgage
69.2% 64.0% 68.7%
Renting property 29.9% 36.0% 31.3%
Secondary school is
highest level of
education
41% NA NA
EQ-5D score (SD) 0.82 (0.26) NA 0.86 (0.23)‡
TTO completion rate 98.5%
NA, not applicable; SD, standard deviation; TTO, time trade-off.
* Six respondents were excluded; three for valuing all states as
identical and less than 1; two for valuing the worst possible state
higher than every other state; one for valuing all states as worse
than dead.
† Statistics for South Yorkshire Health Authority and for England in
the Census 2001. Questions used in this study and the census are
not identical. The census includes persons aged 16 and above
whereas this study only surveys persons aged 18 and above. Age
distribution is here reported as the percentage of all adults aged
18 and over.
‡ Interviews conducted in the Measurement and Valuation ofHealth study in 1993 (Kind et al, 1999).
Table 2 – Summary of psychometric and Rasch analysis used to select items per factor.
Items Item summary Psychometric analysis (n  655) Rasch analysis (n  655)
% response at
floor (very
much)
% response at
ceiling (not at all)
% missing
data
Correlation
with domain
score
SRM Item range Residual Item level
chi-sq
P value
Spread at
logit zero
Disordered DIF
characteristic
Poorly fitting item
in Rasch model
(chi-sq P  0.01)
Physical and role
functioning and
pain
1 Trouble doing
strenuous
activities
28.5 14.4 0.6 0.869 0.206 Sex
2 Trouble taking a
long walk
26.9 16.9 1.1 0.896 0.195 2.576 to 0.516 1.540 0.385 0.93 to 0.37
3 Trouble taking a
short walk
8.1 46.7 1.7 0.844 0.235 Sex
4 Need to stay in
bed or a chair
during the day
9.3 36 1.4 0.788 0.289 1.158 to 2.385 0.874 0.120 0.76 to 0.08
5 Need help with
eating,
dressing,
washing or
using the toilet
4.1 72.8 0.6 0.575 0.313 1.220 to 2.584 0.678 0.083 0.23 to 0.07
6 Limited in doing
your work or
daily activities
18.5 25.8 1.5 0.953 0.259 Yes
7 Limited in
pursuing
hobbies or
other leisure
time activities
17.9 30.1 1.2 0.954 0.237 1.526 to1.192 0.629 0.600 0.82 to 0.23
9 Pain 20 20.2 0.9 0.926 0.499 2.176 to 1.004 4.685 0.075 0.90 to 0.27
19 Pain interfered
with daily
activities
20 30.4 0.5 0.936 0.432 1.427 to 0.987 0.844 0.138 0.81 to 0.27
Social functioning
26 Physical condition
or medical
treatment
interfered with
family life
8.7 49.2 0.8 0.899 0.085 1.247 to 2.013 1.146 0.175 0.78 to 0.12
27 Physical condition
or medical
treatment
interfered with
social life
12.8 41.8 0.6 0.942 0.090 1.869 to 1.144 0.555 0.345 0.87 to 0.24
Emotional functioning
21 Feel tense 6.6 37.7 0.9 0.834 0.264 Age
22 Worried 12.8 26.0 0.2 0.860 0.477 Sex
23 Feel irritable 4.3 44.3 0.5 0.776 0.223 1.546 to 2.740 3.912 0.442 0.82 to 0.06
24 Feel depressed 7.8 41.5 0.8 0.834 0.330 1.696 to 2.017 0.742 0.232 0.85 to 0.12
(continued on next page)
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725V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 2 1 – 7 3 1that responses would not be representative of the full trial pop-
ulation.
Cycle 5 (n  471) was chosen as this is a different time period
where responses have changed (SRM across 27 EORTC items 
0.104), some respondents have side effects and the problem of
attrition is reduced in comparison to later treatment cycles.
Step IV: Valuation study to obtain preferences for the health
state classification
The HSC system describes thousands of health states, meaning it
is impractical to value all states. A sample of health states were
valued by a representative sample of the general population using
TTO. Households in urban and rural areas in North England were
sampled using AFD Names and Numbers version 3.1.25 database
(AFD Software Limited, Ramsey, UK) and the sample was balanced
to the UK population according to ACORN profiles. Health states
were sampled using an orthogonal array to enable the estima-
tion of an additive model for the preference weights. SPSS ver-
sion 15 was used to produce a sample of 81 states using orthog-
onal array and this was supplemented by four additional states
(including the worst state). We chose to value 85 states to enable
an equal number of responses per state, an equal number of
states valued per respondent, and for each respondent to value
the worst state.
At the interview, respondents first self-completed the HSC for
their own health. The QLQ-C30 does notmention cancer, meaning
that respondents were unaware that the health states were asso-
ciated with cancer. One hypothesis is that respondents would
value states differently if cancer was included in the health state
description; this is analyzed elsewhere [26].
Second respondents ranked eight states alongside ‘full health’
nd ‘dead’ to familiarize themselves with the states. Respondents
hen valued a hypothetical ‘practice’ state and the (ranked) eight
tates using the Measurement and Valuation of Health study ver-
ion of TTO including a visual prop designed by the Measurement
nd Valuation of Health group [27]. For each state, respondents
ere first asked if they would prefer the given state for 10 years
fter which they will die, or to die immediately. This determines if
he respondent values the health state as being better than dead,
orse than dead, or equal to being dead. For health states consid-
red better than being dead or dying immediately (BTD), respon-
ents were asked to choose between 1) health state h for w years,
fter which they will die, and 2) full health for z years (zw), after
hich they will die. While w is fixed at 10 years, years in full
ealth, z, is varied to determine the point where respondents are
ndifferent between the two options. For health states considered
orse than being dead or dying immediately (WTD) respondents
ere asked to choose between 1) health state h for w years fol-
owed by full health for z years after which they will die, and 2)
mmediate death. Both years in optimal health, z, and years in
ealth state, w  10-z, are varied to determine the point where
espondents are indifferent between the two options. At the end of
he interview respondents were asked questions covering demo-
raphic and socioeconomic characteristics. Respondents were in-
erviewed in their own home by trained interviewers who had
orked on numerous valuation surveys, such as HUI2 [28] and
AB-5D [16].
The valuation data
Therewere 350 successfully conducted interviews, a response rate
of 40.3% for suitable respondents answering their door at time of
interview. Six respondents were excluded from the analysis; three
for valuing all states as identical and less than one; two for valuing
the worst possible health state higher than every other state; and
one for valuing all states as worse than dead. Characteristics of
included respondents are compared to the general population in
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726 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 2 1 – 7 3 1South Yorkshire and all of England (Table 1). The sample con-
tained a higher proportion of women and people who are aged 41
to 65 years, retired, and in poorer health than the population at
large.
Step V: Modelling to obtain preference weights for the health
state classification
The valuation study elicited utility values for only a sample of
states defined by the HSC. These values are then modelled to pro-
duce utility values for all health states defined by the HSC. This is
achieved through the estimation of preference weights for each
level of each dimension in the HSC.
TTO responses (w,z) were analyzed using a range of different
model specifications. The standard specification is [27]:
ij
s f(X)ij
s,
yij
s1 zij ⁄wij if state better than dead1 zij ⁄ 10 if state worse than dead (1)
here i  1,2 . . . n represents individual health states and j 
,2 . . . m represents respondents. The dependent variable yij
s is TTO
isvalue forhealth state ivaluedby respondent jandX is a vector of
ummy explanatory variables for each level  of dimension 	 of the
HSC. Level  1 acts as a baseline for each dimension.
The second specification is the episodic random utility model
ERUM), where the value of the health state depends on its dura-
ion, wij:
yij
ewijf(X)ij
e,
yij
ewij zij if state better than deadwij zij if state worse than dead (2)
To produce error terms on the same scale as the standard spec-
ification in Equation 1, both zij and wij are divided by 10 before
stimation.
The standard approach transforms WTD TTO responses to
ound value estimates at 1. This has been criticised as there is
ittle empirical evidence for this and arguably transformed re-
ponses cannot be interpreted as being measured on the same
tility scale as states BTD [29]. The ERUMmodel was developed to
eal with this criticism, as responses are not transformed and are
odelled in a way that is consistent with BTD responses [30].
Each model was estimated using ordinary least squares esti-
ation with clusters at the respondent-level, which assumes that
esponses may be correlated within respondent and are indepen-
ent between respondents. Randomandfixed effectsmodelswere
stimated using maximum likelihood estimation for the standard
pproach to take into account individual differences in values [3].
he error term, ij is subdivided as follows:
ijuj eij (3)
where u is individual random effect and e is the random error
Table 3 – Goodness of fit for the Rasch model for each facto
Factor Item-trait interaction
Chi-square
(degrees of freedom)
P
Physical and role functioning
and pain
121.36 (88) 0.
Social functioning 10.82 (8) 0.
Emotional functioning 65.34 (54) 0.
Digestion 72.08 (35) 0.
Fatigue and trouble sleeping 22.05 (20) 0.j ij
erm for the ith health state valuation of the jth individual.Mean level models were estimated where ys
ij, is condensed into
ean estimates, yi, for each ith state. Using the 85 mean esti-
mates, the standard model can be estimated via ordinary least
squares:
y i f(X)i (4)
ean estimates are used as they diminish the effects of outliers in
he distribution of ys
ij. Interaction terms and sociodemographic
ariables are explored for all models.
Performance of all regression models is reported using incon-
istencies, significant coefficients, mean absolute error (MAE) of
ealth state predictions and MAE greater than 5% and 10% and by
xamining plots of actual and predicted health state values. MAE
alculated at the health state level (difference between actual and
redicted values) indicates how large the prediction errors are.
he number of health states valuedwithMAE greater than 5% and
0% indicates if the errors are of a minimal important difference.
nconsistencies in parameter estimates for adjacent levels of an
tem indicated that worsening health did not lead to a lower utility
alue. Models removing these inconsistencies by merging levels
ere estimated.
Results
Health state classification
Step I: Establishing factors
A four factor model on all 27 items accounted for 58.7% of the
variance. All items loaded greater than 0.35 on a factor, but some
items cross-loaded. Factor 1 contained the majority of items [14],
covering physical functioning, role functioning, social function-
ing, pain and items ‘need a rest,’ ‘felt weak,’ and ‘difficulty con-
centrating’. Factor 2 contained all emotional functioning items
plus ‘trouble sleeping’. Factor 3 contained all items covering eating
Fig. 2 – Item map for physical functioning, role functioning
Item fit (SD) Person fit (SD) Person separation
index
–0.58 (2.12) –0.32 (1.02) 0.90
0.85 (0.42) –0.44 (0.80) 0.79
–0.18 (2.14) –0.35 (0.96) 0.85
–0.67 (1.20) –0.30 (0.75) 0.47
0.08 (1.16) –0.65 (1.27) 0.83r.
01
21
14
00and pain dimension.
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727V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 2 1 – 7 3 1and digestion and Factor 4 contained items ‘short of breath,’ ‘were
you tired,’ and ‘difficulty remembering.’ Items loading into Factors
2 and 3were conceptually clear and in accordance with the group-
ing of the QLQ-C30. Items loading into Factors 1 and 4 (17 items),
covered a large range of concepts and further factor analysis was
done on these items to determine if further differentiation was
possible. The additional item ‘trouble sleeping’ was added (18
items in total) over a concern that the initial analysis captured
some causality rather than correlation.
For the additional factor analysis undertaken on the subset of
18 items, a four-factor model explained 67.6% of the variance. All
items loaded greater than 0.35 on a factor, but some items cross-
loaded. The four factors were: physical functioning, role function-
ing, and pain; social functioning; fatigue, trouble sleeping, and
short of breath; and cognitive functioning (principal-component
rotated factor loadings available on request).
Table 2 shows potential items categorized according to fac-
tors for consideration for the HSC. Overall the 27 items can be
divided into six factors: 1) physical functioning, role function-
ing, and pain; 2) social functioning; 3) emotional functioning; 4)
digestion; 5) fatigue, trouble sleeping, and shortness of breath;
and 6) cognitive functioning. Due to the constraints of the size
of the HSC that is amenable to valuation we prioritized factors
showing greater change, greater problems, and greater respon-
siveness with symptoms that were unlikely to be captured
through the other dimensions. Factor analysis, standard psy-
chometric analysis, and preliminary Rasch analysis fed into dis-
cussion at a team meeting that included a clinician to deter-
mine the factors to be analyzed in the Rasch analysis. Cognitive
functioning (Items 20 and 25) and shortness of breath (Item 8)
were excluded from the PBM leaving 24 items across five factors
remaining for further analysis.
Step II: Selecting items and dimensions
Tables 2 and 3 respectively present psychometric analysis and
goodness of fit for the Rasch models estimated for each factor.
Item-level ordering and differential item functioning. Only Item
15 (digestion dimension) was disordered and for this item ‘a little,’
‘quite a bit,’ and ‘very much’ were collapsed into one level. Four
items demonstrated DIF by sex and were split according to sex:
Items 1 and 3 (physical functioning, role functioning and pain di-
mension), Item 15 (digestion), and Item 22 (emotional function-
ing). Item 21 (emotional functioning) demonstrated DIF by age and
was split according to age.
Raschmodel goodness of fit. Three items demonstrated poor item
t (chi-square P 0.01) andwere excluded from subsequent Rasch
models: Item 6 (physical functioning, role functioning, and pain
dimension), Item 14 (digestion), Item 11 (fatigue).
Physical functioning, role functioning, and pain. This factor cov-
ers three separate attributes of quality of life: physical functioning,
role functioning, and pain.
Each item covers only one attribute and it is unlikely that an
item on physical functioning, for example, will capture or reflect
role functioning or pain. To accurately represent the entire factor,
and in accordance with the QLQ-C30 scaling and clinical opinion,
we decided that a minimum of one item each for physical func-
tioning, role functioning, and pain was required.
Out of the five items capturing physical functioning, Items 4
and 5 did not capture the full range of severity but had the highest
SRM, although these were low according to Cohen’s criteria [31].
Item 2 performed well in the Rasch models with relatively high
item fit but had floor effects, relatively low SRM and limited sever-
ity range. Figure 2 shows the itemmap for all items in this dimen- cion, reporting three thresholds between response categories ‘not
t all’ and ‘a little,’ ‘a little’ and ‘quite a bit,’ and ‘quite a bit’ and
very much.’ No item captured the full severity range because
tems 3, 4, and 5 captured severe health, whereas Items 1 and 2
Fig. 3 – EORTC-8D classification system.aptured less severe health. Given that none on the items were
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728 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 2 1 – 7 3 1ideal, Items 2 and 3 were chosen to cover the full severity range
because bothmeasure troublewalking. Items 2 and 3weremerged
to a five-level item in the HSC, with Levels 1 to 4 taken directly
from Item 2 and Level 5 taken from Level 4 of Item 3 (very much
trouble taking a short walk outside of the house).
Of the two role functioning items, Item 7 had good Rasch
model item fit and relatively good item range (Fig. 2), but ceiling
effects. Item 6 performed similarly to Item 7 for the psychomet-
ric analysis, but had poor Rasch model item fit. Therefore Item 7
was selected.
Items 9 and 19 capture pain. Item 9 had a large severity range,
but poor item fit, very high item fit residual, and low item level P
alue suggesting the item contributes poorly to the dimension.
tem 19 was chosen as although it had a more limited range and
ore evidence of ceiling effects it had better item fit.
Social functioning. Of the two social functioning items, Item 27
was chosen as it performs marginally better psychometrically as
Item 26 had a slightly higher degree of ceiling effects, higher item
fit residual and lower P value.
Emotional functioning. Items 21 and 22 suffered from DIF. Items
3 and 24 performed similarly across all criteria. Item 23 had a
arger severity range than Item 24, but also had a higher item fit
esidual, suggesting greater divergence between expected and
bserved responses. Item 24 was chosen as it overall performs
est.
Fatigue and sleep disturbance. Items 10, 12 and 18 performed
similarly, with large severity range and no large ceiling or floor
effects. However, Item10 had a relatively high itemfit residual and
Item 12 had a low item P value, indicating it does not contribute
well to the dimension. Item 18 was selected as it performed mar-
ginally better, with a relatively high P value, low residual, large
coverage at logit zero, and large range.
Digestion. None of the digestion items performed well in psy-
chometric or Rasch analysis. Despite this, they were included in
the HSC as it was believed that they were clinically important
for patients with multiple myeloma. These items capture mul-
tiple symptoms of digestion-related problems: lack of appetite,
Table 4 – Summary of EORTC QLQ-C30 items included in
the EORTC-8D descriptive system.
EORTC-8D
dimension
EORTC
QLQ-C30
items
Question
Physical functioning 2 Trouble taking a long walk
3 Extra level added from ‘trouble
taking a short walk’
Role functioning 7 Limited in pursuing hobbies or
other leisure time activities
Pain 19 Pain interfere with daily
activities
Social functioning 27 Physical condition or medical
treatment interfered with
social life
Emotional functioning 24 Feel depressed
Nausea 14 Felt nauseated
Constipation and
diarrhoea
16 Constipated
17 Diarrhoea
Fatigue and trouble
sleeping
18 Tirednausea, vomiting, constipation, and diarrhea. Lack of appetite,nausea, and vomiting (Items 13, 14, and 15) are all closely re-
lated symptoms, and constipation and diarrhea (Items 16 and
17) are bowel symptoms, suggesting the items can be separated
into two attributes. Item 13 was the only item from appetite,
nausea, and vomiting that did not suffer from DIF, item-level
disordering, or poor item fit. However, this item performed
poorly in the Rasch model with small coverage at logit zero and
high item fit residuals. After consultation amongst our research
team, including our clinical specialist, Item 13, which captures
lack of appetite, was not chosen because it may be thought to be
a desirable (positive) symptom by some people and may be a
symptom due to the age of the population rather than the con-
dition. Therefore, despite suffering from problems in the Rasch
model, Items 14 and 15 were considered because it was believed
to be important to capture appetite, nausea, or vomiting in the
HSC. Both items suffer from large ceiling effects and have low
SRM, with Item 14 performing marginally better. Therefore Item
14 (nausea) was chosen for the HSC.
Items 16 and 17 for constipation and diarrhea perform sim-
ilarly, both suffering from extreme ceiling effects, small spread
at logit zero and high residuals. It was decided to combine these
items because they are both bowel symptoms and respondents
rarely experience both during a weekly period. The items were
combined such that Level 1 of the merged item captures no
bowel (constipation or diarrhea) problems, Levels 2, 3, and 4
capture ‘a little,’ ‘quite a bit,’ and ‘very much’ constipation
and/or diarrhea.
Health state classification. Following the factor analysis, the Ra-
sch analysis was conducted on five factors. To ensure the HSC
retains the attributes of quality of life in each factor, two of the
factors are each represented bymultiple items (physical function-
ing, role functioning, pain, and digestion). To make the TTO valu-
ation easier and health states clearer for respondents in the valu-
ation study these factors have been separated into their separate
attributes and these form the dimensions for the HSC. Thismeans
that the final HSC has eight dimensions (physical functioning, role
functioning, pain, emotional functioning, social functioning, fa-
tigue and sleep disturbance, nausea, constipation and diarrhea)
made up of 10 items. The dimension and item selections were
validated using Cycle 5 data following the process described above
for Steps I and II (results available from authors on request). An
example health state is shown in Figure 3. Table 4 summarizes the
QLQ-C30 items chosen for each dimension of the HSC. Figure 4
presents the HSC where a health state is made up of eight sen-
tences and hence has an eight-digit identifier, from best state
11111111 to worst state 54444444. This system generates a total of
81,920 health states.Fig. 4 – Example health state description (51224434).
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Mean TTO values varied from 0.95 for best state to 0.13 for worst
state (available on request), which suggests that on average all
states were valued as better than being dead. Of the total 2710
TTO observations, 514 observations (19%) were equal to 1
(equivalent in value to full health) and 271 (10%) were less than
or equal to 0 (valued as the same or worse than being dead).
Step V: Modelling health state values
Table 5 presents the preference weights estimated using a vari-
ty of regression models. All coefficients have the expected sign
i.e., Level 1 on each dimension is the reference point and higher
evels increase TTO disvalue), and are consistent (i.e., more se-
ere levels have larger coefficients and incrementally increase
TO disvalue) with the exception of physical functioning Levels
and 5 and nausea Levels 2 and 3. The majority of coefficients
re statistically significant. Models 1 and 2 are specified in Equa-
ion 1, Model 3 is specified in Equation 2, and Models 4 and 5 are
ean level models specified in Equation 4. Model 2 is a random
ffects model because the Hausman test confirmed that a fixed
ffects model would render similar estimates at reduced effi-
iency. Model 5 is a consistent version of Model 4 where adja-
ent inconsistent levels are merged into a common dummy
Table 5 – Estimated preference weights.
Dimensions and levels (1) OLS (2) MLE
RE
(3
PF2 0.061 0.052
PF3 0.076 0.079
PF4 0.135 0.134
PF5 0.121 0.127
RF2 0.026 0.023
RF3 0.042 0.052
RF4 0.082 0.090
PAIN2 0.059 0.041
PAIN3 0.060 0.060
PAIN4 0.070 0.083
EF2 0.028 0.027
EF3 0.063 0.072
EF4 0.157 0.160
SF2 0.025 0.022
SF3 0.059 0.065
SF4 0.173 0.174
FAT2 0.046 0.026
FAT3 0.052 0.031
FAT4 0.104 0.064
NAU2 0.031 0.036
NAU3 0.015 0.037
NAU4 0.062 0.079
CD2 0.012 0.022
CD3 0.050 0.037
CD4 0.078 0.070
Observations 2710 2710
R-squared 0.60
Number of id 344
Inconsistencies 2 1
Insignificant level coefficients 5 5
MAE 0.052 0.054
MAE  0.05 41 41
MAE  0.10 9 13
Note: Figures in bold have t-statistics significant at the 5% level.
PF, Physical functioning; RF, Role functioning; PAIN, Pain; EF, Emoti
Constipation and/or diarrhea; PF23, Physical functioning at Level 2 oariable.Mean absolute errorwas similar betweenmodels, ranging from
0.046 to 0.054. The number of health states with MAE greater than
5% ranges from33 to 41 andMAE greater than 10% ranges from6 to
13. Models including interaction effects and sociodemographic
variableswere estimated (available on request) but predictive abil-
ity, inconsistencies, and significant coefficients for the main ef-
fects variables were not improved.
Conclusions
We have estimated a PBM for the QLQ-C30 using methodology
applied in the development of the SF-6D from the SF-36 [3] and a
number of condition-specificmeasures [14-17]. The derived PBM is
the EORTC-8D, which consists of a classification system and a
scoring system that estimates health state utility values for all
health states. The classification system was constructed using
classical psychometric, factor, and Rasch analysis to ensure that
chosen items appropriately reflected their dimension and that
each dimension covered a wide range of severity. A sample of
states was valued using TTO and the values modelled using a
variety of specifications. The estimated preferenceweights enable
utility scores to be generated directly from QLQ-C30 datasets.
In the transition from the profile EORTC QLQ-C30 to the pref-
M OLS (4) Mean model (5) Consistent
mean model
.052 0.065 PF2 0.065
.077 0.078 PF3 0.078
.103 0.139 PF45 0.127
.104 0.105
.044 0.032 RF2 0.032
.050 0.045 RF3 0.045
.076 0.079 RF4 0.078
.054 0.059 PAIN2 0.059
.064 0.062 PAIN3 0.062
.070 0.065 PAIN4 0.064
.032 0.030 EF2 0.030
.053 0.066 EF3 0.066
.132 0.150 EF4 0.149
.029 0.027 SF2 0.027
.046 0.059 SF3 0.059
.132 0.163 SF4 0.163
.038 0.046 FAT2 0.047
.052 0.054 FAT3 0.054
.084 0.093 FAT4 0.092
.025 0.032 NAU23 0.026
.027 0.019
.052 0.057 NAU4 0.056
.011 0.016 CD2 0.016
.035 0.052 CD3 0.052
.059 0.073 CD4 0.072
85 85
.56 0.97 0.97
2 0
6 5
.046 0.050 0.051
37 39
8 9
functioning; SF, Social functioning; FAT, Fatigue; NAU, Nausea; CD,
AU23, Nausea at Level 2 or 3.) ERU
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2710
0
0
3
0
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6
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730 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 2 1 – 7 3 1original measure were excluded due to the unavoidable prioritisa-
tion required to ensure the HSC was amenable to valuation. A
general concern regarding the development of PBMs from existing
questionnaires is that the HSC is strongly influenced by the spe-
cific patient dataset used for its development. The HSC was devel-
oped using data from newly diagnosed multiple myeloma pa-
tients. A potential weakness of the classification system is that it
does not capture the excluded dimensions of shortness of breath
and cognitive functioning. Further testing of the classification will
be undertaken across datasets of cancer patients with different
types of cancers to determine if it is appropriate for patients with
other types of cancers. This project is the first stage of a wider
collaborative project producing a preference-based measure for
the QLQ-C30 across different countries and different types of can-
cers. The classification system will be rigorously tested at later
stages of this project and alternative methods will be explored to
establish the dimensionality of themeasure in Step 1. If it is shown
that the classification systemdoes not capture all dimensions that
are important or appropriate for a cancer patient group, one pos-
sibility is to add-on additional dimensions onto the EORTC-8D core
to capture these missing dimensions. This possibility has been
explored for both the generic EQ-5Dmeasure [32] and asthma con-
dition-specific AQL-5D [33] and is an area requiring further re-
earch. A further consideration is that although the patient data-
et used to derive the HSC is international, the valuation study
eported here was conducted in the United Kingdom. Previous
esearch suggests that preference weights differ across different
ountries and cultures [34,35], meaning the preference weights
resented here may be more appropriate for trials in the United
ingdom.
For use in cost-utility analysis preference weights should be
onsistent;meaning health state values should decrease as health
orsens. Regression models based on the standard specification
roduced inconsistencies for physical functioning levels 4 and 5.
his may have been due to themerging of items in the QLQ-C30 to
orm this dimension. Models 1 and 4 also produce inconsistencies
or nausea levels 2 and 3. Model 5 removes these inconsistencies
y merging adjacent levels. Models 3 and 5 perform best overall,
ccording to predictive ability and consistent and significant coef-
cients. Model 5 has a predicted range of utilities from 0.199 to 1,
hereas Model 3 has a predicted range of 0.291 to 1, meaning that
he worst state defined by the HSC has a much lower value using
reference weights estimated using Model 5. Deciding on the pre-
erred model comes down to a choice between the Mean Model 5
ith no inconsistencies, as chosen both in the valuation of the
F-6D (4) and the overactive-bladder-specific measure (16), or the
ecently developed ERUM specification. Although Model 5 is in
ccordance with the recommended value set of many similar
easures, the ERUM Model 3 is the preferred model here because
t more appropriately deals with TTO values for WTD and per-
orms best, using all criteria.
An important concern is that often condition-specific mea-
ures fail to capture comorbidities and side effects of treatments,
nd hence are not strictly comparable to generic measures when
sed to estimate QALYs for resource allocation. One way to en-
ance comparability acrossmeasures is for allmeasures to use the
ame methodology to derive values [6]. Our valuation study fol-
owed the methodology used in the development of generic mea-
ures: we implemented the protocol used to derive the UK EQ-5D
reference weights [27]; used common anchors of one for full
ealth and zero for dead; and interviews were conducted using a
ample of the general population. Furthermore, the EORTC-8D de-
criptive system captures a wide range of dimensions including
eneric dimensions such as physical functioning and role func-
ioning, aswell asmore condition-specific symptoms such as nau-
ea, constipation, and diarrhea. Therefore the descriptive systems likely to capture overall health-related quality of life, including
oth comorbidities and side-effects.
The EORTC-8D was developed out of a concern that generic
easures were not appropriate to measure the quality of life of
ancer patients [7]. The EORTC-8D enables QALYs to be directly
stimated using the QLQ-C30, a questionnaire typically included
n cancer trials, rather than the use of generic measures that are
ess appropriate [7] or mapping to generic measures that is both
ess appropriate and increases error around utility estimates. It is
oped that thismeasurewill provide appropriate and useful infor-
ation for cost per QALY analysis undertaken in cancer trials.
his study forms part of a wider cross-country study that will
xamine the use of PBMs from the QLQ-C30 in a variety of coun-
ries and different patient groups.
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